# American Outdoor Brands, Inc.: financial statements, quarterly

AOUT · Nasdaq · CIK 1808997 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/aout.md) · [Financials](/companies/aout/financials.md) · [Filings](/companies/aout/filings.md) · [Insiders](/companies/aout/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aout/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [57.9](/filings/0000950170-24-133687.md) | [53.4](/filings/0000950170-25-034660.md) | [46.3 d](/filings/0001808997-26-000031.md) | [41.6](/filings/0001808997-25-000035.md) | [60.2](/filings/0001808997-25-000065.md) | [58.5](/filings/0001808997-26-000011.md) | [61.9 d](/filings/0001808997-26-000031.md) | [29.7](/filings/0001808997-26-000046.md) | [57.2](/filings/0001808997-25-000065.md) | [56.6](/filings/0001808997-26-000011.md) | [47.1 d](/filings/0001808997-26-000031.md) | [37.3](/filings/0001808997-26-000046.md) |
| Cost of revenue | $m | [31.4](/filings/0000950170-24-133687.md) | [30.6](/filings/0000950170-25-034660.md) | [26.9 d](/filings/0001808997-26-000031.md) | [22.7](/filings/0001808997-25-000035.md) | [31.3](/filings/0001808997-25-000065.md) | [32.4](/filings/0001808997-26-000011.md) | [36.6 d](/filings/0001808997-26-000031.md) | [15.8](/filings/0001808997-26-000046.md) | [31.1](/filings/0001808997-25-000065.md) | [33.4](/filings/0001808997-26-000011.md) | [25.0 d](/filings/0001808997-26-000031.md) | [17.5](/filings/0001808997-26-000046.md) |
| Gross profit | $m | [26.5](/filings/0000950170-24-133687.md) | [22.8](/filings/0000950170-25-034660.md) | [19.4 d](/filings/0001808997-26-000031.md) | [18.9](/filings/0001808997-25-000035.md) | [28.9](/filings/0001808997-25-000065.md) | [26.1](/filings/0001808997-26-000011.md) | [25.3 d](/filings/0001808997-26-000031.md) | [13.9](/filings/0001808997-26-000046.md) | [26.1](/filings/0001808997-25-000065.md) | [23.2](/filings/0001808997-26-000011.md) | [22.1 d](/filings/0001808997-26-000031.md) | [19.7](/filings/0001808997-26-000046.md) |
| Research and development | $m | [1.7](/filings/0000950170-24-133687.md) | [1.8](/filings/0000950170-25-034660.md) | [1.8 d](/filings/0001808997-26-000031.md) | [1.7](/filings/0001808997-25-000035.md) | [1.9](/filings/0001808997-25-000065.md) | [1.9](/filings/0001808997-26-000011.md) | [2.2 d](/filings/0001808997-26-000031.md) | [2.0](/filings/0001808997-26-000046.md) | [1.2](/filings/0001808997-25-000065.md) | [1.3](/filings/0001808997-26-000011.md) | [1.6 d](/filings/0001808997-26-000031.md) | [1.6](/filings/0001808997-26-000046.md) |
| Operating income | $m | [(0.0)](/filings/0000950170-24-133687.md) | [(2.9)](/filings/0000950170-25-034660.md) | [(5.5) d](/filings/0001808997-26-000031.md) | [(2.6)](/filings/0001808997-25-000035.md) | [3.1](/filings/0001808997-25-000065.md) | [0.3](/filings/0001808997-26-000011.md) | [(1.0) d](/filings/0001808997-26-000031.md) | [(6.8)](/filings/0001808997-26-000046.md) | [2.1](/filings/0001808997-25-000065.md) | [(3.9)](/filings/0001808997-26-000011.md) | [(0.4) d](/filings/0001808997-26-000031.md) | [(2.1)](/filings/0001808997-26-000046.md) |
| Income tax | $m | [(0.0)](/filings/0000950170-24-133687.md) | [0.0](/filings/0000950170-25-034660.md) | [(0.1) d](/filings/0001808997-26-000031.md) | [0.0](/filings/0001808997-25-000035.md) | [0.0](/filings/0001808997-25-000065.md) | [0.1](/filings/0001808997-26-000011.md) | [0.0 d](/filings/0001808997-26-000031.md) | [0.1](/filings/0001808997-26-000046.md) | [0.0](/filings/0001808997-25-000065.md) | [0.0](/filings/0001808997-26-000011.md) | [(0.0) d](/filings/0001808997-26-000031.md) | [0.0](/filings/0001808997-26-000046.md) |
| Net income | $m | [0.1](/filings/0000950170-24-133687.md) | [(2.9)](/filings/0000950170-25-034660.md) | [(5.3) d](/filings/0001808997-26-000031.md) | [(2.4)](/filings/0001808997-25-000035.md) | [3.1](/filings/0001808997-25-000065.md) | [0.2](/filings/0001808997-26-000011.md) | [(1.0) d](/filings/0001808997-26-000031.md) | [(6.8)](/filings/0001808997-26-000046.md) | [2.1](/filings/0001808997-25-000065.md) | [(4.1)](/filings/0001808997-26-000011.md) | [(0.4) d](/filings/0001808997-26-000031.md) | [(1.5)](/filings/0001808997-26-000046.md) |
| Diluted EPS | $ per share | [0.01](/filings/0000950170-24-133687.md) | [(0.23)](/filings/0000950170-25-034660.md) | not reported | [(0.18)](/filings/0001808997-25-000035.md) | [0.24](/filings/0001808997-25-000065.md) | [0.01](/filings/0001808997-26-000011.md) | not reported | [(0.54)](/filings/0001808997-26-000046.md) | [0.16](/filings/0001808997-25-000065.md) | [(0.32)](/filings/0001808997-26-000011.md) | not reported | [(0.12)](/filings/0001808997-26-000046.md) |
| Basic EPS | $ per share | [0.01](/filings/0000950170-24-133687.md) | [(0.23)](/filings/0000950170-25-034660.md) | not reported | [(0.18)](/filings/0001808997-25-000035.md) | [0.24](/filings/0001808997-25-000065.md) | [0.01](/filings/0001808997-26-000011.md) | not reported | [(0.54)](/filings/0001808997-26-000046.md) | [0.16](/filings/0001808997-25-000065.md) | [(0.32)](/filings/0001808997-26-000011.md) | not reported | [(0.12)](/filings/0001808997-26-000046.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.4](/filings/0000950170-23-067039.md) | [15.9](/filings/0000950170-24-027969.md) | [29.7](/filings/0001808997-25-000014.md) | [23.5](/filings/0000950170-24-104003.md) | [14.2](/filings/0000950170-24-133687.md) | [17.1](/filings/0000950170-25-034660.md) | [23.4](/filings/0001808997-26-000031.md) | [17.8](/filings/0001808997-25-000035.md) | [3.1](/filings/0001808997-25-000065.md) | [10.4](/filings/0001808997-26-000011.md) | [21.4](/filings/0001808997-26-000046.md) | [33.3](/filings/0001808997-26-000046.md) |
| Current assets | $m | [164](/filings/0000950170-23-067039.md) | [150](/filings/0000950170-24-027969.md) | [155](/filings/0001808997-25-000014.md) | [162](/filings/0000950170-24-104003.md) | [174](/filings/0000950170-24-133687.md) | [168](/filings/0000950170-25-034660.md) | [172](/filings/0001808997-26-000031.md) | [170](/filings/0001808997-25-000035.md) | [171](/filings/0001808997-25-000065.md) | [159](/filings/0001808997-26-000011.md) | [163](/filings/0001808997-26-000046.md) | [167](/filings/0001808997-26-000046.md) |
| Total assets | $m | [244](/filings/0000950170-23-067039.md) | [239](/filings/0000950170-24-027969.md) | [241](/filings/0001808997-25-000014.md) | [245](/filings/0000950170-24-104003.md) | [254](/filings/0000950170-24-133687.md) | [246](/filings/0000950170-25-034660.md) | [246](/filings/0001808997-26-000031.md) | [242](/filings/0001808997-25-000035.md) | [241](/filings/0001808997-25-000065.md) | [225](/filings/0001808997-26-000011.md) | [227](/filings/0001808997-26-000046.md) | [229](/filings/0001808997-26-000046.md) |
| Current liabilities | $m | [34.0](/filings/0000950170-23-067039.md) | [23.0](/filings/0000950170-24-027969.md) | [29.4](/filings/0001808997-25-000014.md) | [36.1](/filings/0000950170-24-104003.md) | [42.6](/filings/0000950170-24-133687.md) | [34.9](/filings/0000950170-25-034660.md) | [36.8](/filings/0001808997-26-000031.md) | [42.2](/filings/0001808997-25-000035.md) | [38.9](/filings/0001808997-25-000065.md) | [28.1](/filings/0001808997-26-000011.md) | [29.9](/filings/0001808997-26-000046.md) | [33.8](/filings/0001808997-26-000046.md) |
| Total liabilities | $m | [57.7](/filings/0000950170-23-067039.md) | [56.7](/filings/0000950170-24-027969.md) | [62.7](/filings/0001808997-25-000014.md) | [69.1](/filings/0000950170-24-104003.md) | [75.3](/filings/0000950170-24-133687.md) | [67.2](/filings/0000950170-25-034660.md) | [68.7](/filings/0001808997-26-000031.md) | [74.1](/filings/0001808997-25-000035.md) | [70.5](/filings/0001808997-25-000065.md) | [59.3](/filings/0001808997-26-000011.md) | [60.7](/filings/0001808997-26-000046.md) | [64.2](/filings/0001808997-26-000046.md) |
| Shareholders' equity | $m | [186](/filings/0000950170-25-034660.md) | [182](/filings/0000950170-25-034660.md) | [178](/filings/0001808997-26-000031.md) | [176](/filings/0001808997-25-000065.md) | [179](/filings/0001808997-26-000011.md) | [179](/filings/0001808997-26-000011.md) | [178](/filings/0001808997-26-000046.md) | [168](/filings/0001808997-26-000046.md) | [170](/filings/0001808997-26-000011.md) | [166](/filings/0001808997-26-000011.md) | [166](/filings/0001808997-26-000046.md) | [164](/filings/0001808997-26-000046.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.4) d](/filings/0000950170-24-133687.md) | [13.0 d](/filings/0000950170-25-034660.md) | [14.7 d](/filings/0001808997-26-000031.md) | [(4.4)](/filings/0001808997-25-000035.md) | [(7.9) d](/filings/0001808997-25-000065.md) | [5.9 d](/filings/0001808997-26-000011.md) | [7.8 d](/filings/0001808997-26-000031.md) | [(1.7)](/filings/0001808997-26-000046.md) | [(13.3) d](/filings/0001808997-25-000065.md) | [9.9 d](/filings/0001808997-26-000011.md) | [11.4 d](/filings/0001808997-26-000031.md) | [13.0](/filings/0001808997-26-000046.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-133687.md) | [3.3 d](/filings/0000950170-25-034660.md) | [0.5 d](/filings/0001808997-26-000031.md) | [0.8](/filings/0001808997-25-000035.md) | [0.1 d](/filings/0001808997-25-000065.md) | [1.7 d](/filings/0001808997-26-000011.md) | [0.6 d](/filings/0001808997-26-000031.md) | [0.3](/filings/0001808997-26-000046.md) | [0.8 d](/filings/0001808997-25-000065.md) | [0.9 d](/filings/0001808997-26-000011.md) | [0.0 d](/filings/0001808997-26-000031.md) | [0.1](/filings/0001808997-26-000046.md) |
| Share repurchases | $m | [1.5 d](/filings/0000950170-24-133687.md) | [1.8 d](/filings/0000950170-25-034660.md) | [0.5 d](/filings/0001808997-26-000031.md) | [0.4](/filings/0001808997-25-000035.md) | [1.0 d](/filings/0001808997-25-000065.md) | [1.2 d](/filings/0001808997-26-000011.md) | [1.2 d](/filings/0001808997-26-000031.md) | [2.5](/filings/0001808997-26-000046.md) | [0.7 d](/filings/0001808997-25-000065.md) | [1.4 d](/filings/0001808997-26-000011.md) | [0.5 d](/filings/0001808997-26-000031.md) | [0.0](/filings/0001808997-26-000046.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-10-31) | Q3 FY2023 (2023-01-31) | Q1 FY2024 (2023-07-31) | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.6](/filings/0000950170-23-067039.md) | [13.3](/filings/0000950170-24-027969.md) | [13.2](/filings/0000950170-24-104003.md) | [13.3](/filings/0000950170-24-133687.md) | [12.9](/filings/0000950170-25-034660.md) | [12.9](/filings/0001808997-25-000035.md) | [13.1](/filings/0001808997-25-000065.md) | [13.1](/filings/0001808997-26-000011.md) | [12.7](/filings/0001808997-26-000046.md) | [12.9](/filings/0001808997-25-000065.md) | [12.5](/filings/0001808997-26-000011.md) | [12.6](/filings/0001808997-26-000046.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,621,225 at 2026-08-31, from the cover of the [10-Q filed 2026-09-03](/filings/0001808997-26-000046.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.